510 related articles for article (PubMed ID: 7859582)
21. 24-hour intragastric acidity and plasma gastrin after omeprazole treatment and after proximal gastric vagotomy in duodenal ulcer patients.
Lind T; Cederberg C; Olausson M; Olbe L
Gastroenterology; 1990 Dec; 99(6):1593-8. PubMed ID: 2227275
[TBL] [Abstract][Full Text] [Related]
22. Relationship between inhibition of acid secretion and healing of peptic ulcers.
Chiverton SG; Hunt RH
Scand J Gastroenterol Suppl; 1989; 166():43-7; discussion 74-5. PubMed ID: 2690331
[TBL] [Abstract][Full Text] [Related]
23. Impact of acid-related disorders in the United States.
Brown M; Yang RD
Manag Care; 2001 Oct; 10(10 Suppl):7-10. PubMed ID: 11729446
[TBL] [Abstract][Full Text] [Related]
24. Twenty-four-hour intragastric pH-metry: H2-receptor antagonist restoration of nightly gastric spontaneous alkalinization in duodenal ulcer healing.
Bianco A; Cagossi M; Piraccini R; Greco AV
Riv Eur Sci Med Farmacol; 1992; 14(5):281-91. PubMed ID: 1364062
[TBL] [Abstract][Full Text] [Related]
25. The effect of 20 Mg omeprazole daily on serum gastrin, 24-h intragastric acidity, and bile acid concentration in duodenal ulcer patients.
Naesdal J; Bankel M; Bodemar G; Gotthard R; Lundquist G; Walan A
Scand J Gastroenterol; 1987 Jan; 22(1):5-12. PubMed ID: 3551048
[TBL] [Abstract][Full Text] [Related]
26. Effect of omeprazole, a substituted benzimidazole, on 24-h intragastric acidity in patients with peptic ulcer disease.
Naesdal J; Bodemar G; Walan A
Scand J Gastroenterol; 1984 Oct; 19(7):916-22. PubMed ID: 6531660
[TBL] [Abstract][Full Text] [Related]
27. Clinical perspectives of drugs inhibiting acid secretion--H+K+-ATPase inhibitors.
Walan A
Scand J Gastroenterol Suppl; 1986; 125():50-4. PubMed ID: 3029857
[TBL] [Abstract][Full Text] [Related]
28. Interrelationship between gastric acidity and gastrin concentration in patients with duodenal or gastric ulcer and in healthy subjects.
Mahachai V; Walker K; Pinchbeck B; Thomson AB
Clin Ther; 1985; 7(4):424-41. PubMed ID: 4016826
[TBL] [Abstract][Full Text] [Related]
29. Gastric acid secretion and intragastric acidity: measurement in health and disease.
Pounder RE; Fraser AG
Baillieres Clin Gastroenterol; 1993 Mar; 7(1):55-80. PubMed ID: 8097412
[TBL] [Abstract][Full Text] [Related]
30. Optimizing acid-suppression therapy.
Barnett JL; Robinson M
Manag Care; 2001 Oct; 10(10 Suppl):17-21. PubMed ID: 11729443
[TBL] [Abstract][Full Text] [Related]
31. Idiopathic gastric acid hypersecretion: treatment implications for refractory acid/peptic disorders.
Lewis JH
Aliment Pharmacol Ther; 1991; 5 Suppl 1():15-24. PubMed ID: 1888834
[TBL] [Abstract][Full Text] [Related]
32. [A clinical study of pathophysiology and treatment of intractable gastric ulcers based on 24-hour intragastric pH monitoring].
Sakaguchi M
Nihon Shokakibyo Gakkai Zasshi; 1993 Apr; 90(4):765-73. PubMed ID: 8098380
[TBL] [Abstract][Full Text] [Related]
33. Twenty-four-hour intragastric acidity and plasma gastrin concentration before and during treatment with either ranitidine or omeprazole.
Lanzon-Miller S; Pounder RE; Hamilton MR; Ball S; Chronos NA; Raymond F; Olausson M; Cederberg C
Aliment Pharmacol Ther; 1987 Jun; 1(3):239-51. PubMed ID: 2979226
[TBL] [Abstract][Full Text] [Related]
34. The relationship between suppression of acidity and gastric ulcer healing rates.
Howden CW; Hunt RH
Aliment Pharmacol Ther; 1990 Feb; 4(1):25-33. PubMed ID: 2151756
[TBL] [Abstract][Full Text] [Related]
35. Omeprazole (20 mg) daily given in the morning or evening: a comparison of effects on gastric acidity, and plasma gastrin and omeprazole concentration.
Chiverton SG; Howden CW; Burget DW; Hunt RH
Aliment Pharmacol Ther; 1992 Feb; 6(1):103-11. PubMed ID: 1543812
[TBL] [Abstract][Full Text] [Related]
36. Concomitant Administration of a Histamine2 Receptor Antagonist and Proton Pump Inhibitor Enhances Gastric Acid Suppression.
Abdul-Hussein M; Freeman J; Castell D
Pharmacotherapy; 2015 Dec; 35(12):1124-9. PubMed ID: 26621819
[TBL] [Abstract][Full Text] [Related]
37. [Effect of H2-receptor antagonist and proton pomp inhibitor on the treatment of acid-related disease].
Kawai T; Yagi K; Moriyasu F
Nihon Rinsho; 2015 Jul; 73(7):1159-62. PubMed ID: 26165073
[TBL] [Abstract][Full Text] [Related]
38. [Endoscopic stage classification of peptic ulcer and characterization of the healing process by proton pump inhibitors].
Karasawa H; Miwa T
Nihon Rinsho; 1992 Jan; 50(1):74-80. PubMed ID: 1347333
[TBL] [Abstract][Full Text] [Related]
39. Review article: gastric acidity--comparison of esomeprazole with other proton pump inhibitors.
Hatlebakk JG
Aliment Pharmacol Ther; 2003 Feb; 17 Suppl 1():10-5; discussion 16-7. PubMed ID: 12614300
[TBL] [Abstract][Full Text] [Related]
40. Ranitidine in the treatment of duodenal ulcer disease: relationship between antisecretory effect and ulcer healing rate.
McIsaac RL; Dixon JS; Mills JG; Wood JR
Aliment Pharmacol Ther; 1991 Jun; 5(3):227-43. PubMed ID: 1888823
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
